Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions

Daphne C Ang, Andrea L. Warrick, Amy Shilling, Carol Beadling, Christopher Corless, Megan Troxell

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The phosphatidylinositol-3-kinase pathway is one of the most commonly altered molecular pathways in invasive breast carcinoma, with phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) mutations in 25% of invasive carcinomas. Ductal carcinoma in situ (DCIS), benign papillomas, and small numbers of columnar cell lesions harbor an analogous spectrum of PIK3CA and AKT1 mutations, yet there is little data on usual ductal hyperplasia and atypical ductal and lobular neoplasias. We screened 192 formalin-fixed paraffin-embedded breast lesions from 75 patients for point mutations using a multiplexed panel encompassing 643 point mutations across 53 genes, including 58 PIK3CA substitutions. PIK3CA point mutations were identified in 31/62 (50%) proliferative lesions (usual ductal hyperplasia and columnar cell change), 10/14 (71%) atypical hyperplasias (atypical ductal hyperplasia and flat epithelial atypia), 7/16 (44%) lobular neoplasias (atypical lobular hyperplasia and lobular carcinoma in situ), 10/21 (48%) DCIS, and 13/37 (35%) invasive carcinomas. In genotyping multiple lesions of different stage from the same patient/specimen, we found considerable heterogeneity; most notably, in 12 specimens the proliferative lesion was PIK3CA mutant but the concurrent carcinoma was wild type. In 11 additional specimens, proliferative epithelium and cancer contained different point mutations. The frequently discordant genotypes of usual ductal hyperplasia/columnar cell change and concurrent carcinoma support a role for PIK3CA-activating point mutations in breast epithelial proliferation, perhaps more so than transformation. Further, these data suggest that proliferative breast lesions are heterogeneous and may represent non-obligate precursors of invasive carcinoma.

Original languageEnglish (US)
Pages (from-to)740-750
Number of pages11
JournalModern Pathology
Volume27
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Phosphatidylinositol 3-Kinase
Carcinoma, Intraductal, Noninfiltrating
Point Mutation
Breast
Hyperplasia
Carcinoma
Mutation
Neoplasms
Papilloma
Paraffin
Formaldehyde
Catalytic Domain
Epithelium
Cell Count
Genotype
Breast Neoplasms
Genes

Keywords

  • atypical ductal hyperplasia
  • breast carcinoma
  • columnar cell change
  • PIK3CA
  • usual ductal hyperplasia

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions. / C Ang, Daphne; Warrick, Andrea L.; Shilling, Amy; Beadling, Carol; Corless, Christopher; Troxell, Megan.

In: Modern Pathology, Vol. 27, No. 5, 2014, p. 740-750.

Research output: Contribution to journalArticle

C Ang, Daphne ; Warrick, Andrea L. ; Shilling, Amy ; Beadling, Carol ; Corless, Christopher ; Troxell, Megan. / Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions. In: Modern Pathology. 2014 ; Vol. 27, No. 5. pp. 740-750.
@article{698e206825f746e5a904be026273023b,
title = "Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions",
abstract = "The phosphatidylinositol-3-kinase pathway is one of the most commonly altered molecular pathways in invasive breast carcinoma, with phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) mutations in 25{\%} of invasive carcinomas. Ductal carcinoma in situ (DCIS), benign papillomas, and small numbers of columnar cell lesions harbor an analogous spectrum of PIK3CA and AKT1 mutations, yet there is little data on usual ductal hyperplasia and atypical ductal and lobular neoplasias. We screened 192 formalin-fixed paraffin-embedded breast lesions from 75 patients for point mutations using a multiplexed panel encompassing 643 point mutations across 53 genes, including 58 PIK3CA substitutions. PIK3CA point mutations were identified in 31/62 (50{\%}) proliferative lesions (usual ductal hyperplasia and columnar cell change), 10/14 (71{\%}) atypical hyperplasias (atypical ductal hyperplasia and flat epithelial atypia), 7/16 (44{\%}) lobular neoplasias (atypical lobular hyperplasia and lobular carcinoma in situ), 10/21 (48{\%}) DCIS, and 13/37 (35{\%}) invasive carcinomas. In genotyping multiple lesions of different stage from the same patient/specimen, we found considerable heterogeneity; most notably, in 12 specimens the proliferative lesion was PIK3CA mutant but the concurrent carcinoma was wild type. In 11 additional specimens, proliferative epithelium and cancer contained different point mutations. The frequently discordant genotypes of usual ductal hyperplasia/columnar cell change and concurrent carcinoma support a role for PIK3CA-activating point mutations in breast epithelial proliferation, perhaps more so than transformation. Further, these data suggest that proliferative breast lesions are heterogeneous and may represent non-obligate precursors of invasive carcinoma.",
keywords = "atypical ductal hyperplasia, breast carcinoma, columnar cell change, PIK3CA, usual ductal hyperplasia",
author = "{C Ang}, Daphne and Warrick, {Andrea L.} and Amy Shilling and Carol Beadling and Christopher Corless and Megan Troxell",
year = "2014",
doi = "10.1038/modpathol.2013.197",
language = "English (US)",
volume = "27",
pages = "740--750",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions

AU - C Ang, Daphne

AU - Warrick, Andrea L.

AU - Shilling, Amy

AU - Beadling, Carol

AU - Corless, Christopher

AU - Troxell, Megan

PY - 2014

Y1 - 2014

N2 - The phosphatidylinositol-3-kinase pathway is one of the most commonly altered molecular pathways in invasive breast carcinoma, with phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) mutations in 25% of invasive carcinomas. Ductal carcinoma in situ (DCIS), benign papillomas, and small numbers of columnar cell lesions harbor an analogous spectrum of PIK3CA and AKT1 mutations, yet there is little data on usual ductal hyperplasia and atypical ductal and lobular neoplasias. We screened 192 formalin-fixed paraffin-embedded breast lesions from 75 patients for point mutations using a multiplexed panel encompassing 643 point mutations across 53 genes, including 58 PIK3CA substitutions. PIK3CA point mutations were identified in 31/62 (50%) proliferative lesions (usual ductal hyperplasia and columnar cell change), 10/14 (71%) atypical hyperplasias (atypical ductal hyperplasia and flat epithelial atypia), 7/16 (44%) lobular neoplasias (atypical lobular hyperplasia and lobular carcinoma in situ), 10/21 (48%) DCIS, and 13/37 (35%) invasive carcinomas. In genotyping multiple lesions of different stage from the same patient/specimen, we found considerable heterogeneity; most notably, in 12 specimens the proliferative lesion was PIK3CA mutant but the concurrent carcinoma was wild type. In 11 additional specimens, proliferative epithelium and cancer contained different point mutations. The frequently discordant genotypes of usual ductal hyperplasia/columnar cell change and concurrent carcinoma support a role for PIK3CA-activating point mutations in breast epithelial proliferation, perhaps more so than transformation. Further, these data suggest that proliferative breast lesions are heterogeneous and may represent non-obligate precursors of invasive carcinoma.

AB - The phosphatidylinositol-3-kinase pathway is one of the most commonly altered molecular pathways in invasive breast carcinoma, with phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) mutations in 25% of invasive carcinomas. Ductal carcinoma in situ (DCIS), benign papillomas, and small numbers of columnar cell lesions harbor an analogous spectrum of PIK3CA and AKT1 mutations, yet there is little data on usual ductal hyperplasia and atypical ductal and lobular neoplasias. We screened 192 formalin-fixed paraffin-embedded breast lesions from 75 patients for point mutations using a multiplexed panel encompassing 643 point mutations across 53 genes, including 58 PIK3CA substitutions. PIK3CA point mutations were identified in 31/62 (50%) proliferative lesions (usual ductal hyperplasia and columnar cell change), 10/14 (71%) atypical hyperplasias (atypical ductal hyperplasia and flat epithelial atypia), 7/16 (44%) lobular neoplasias (atypical lobular hyperplasia and lobular carcinoma in situ), 10/21 (48%) DCIS, and 13/37 (35%) invasive carcinomas. In genotyping multiple lesions of different stage from the same patient/specimen, we found considerable heterogeneity; most notably, in 12 specimens the proliferative lesion was PIK3CA mutant but the concurrent carcinoma was wild type. In 11 additional specimens, proliferative epithelium and cancer contained different point mutations. The frequently discordant genotypes of usual ductal hyperplasia/columnar cell change and concurrent carcinoma support a role for PIK3CA-activating point mutations in breast epithelial proliferation, perhaps more so than transformation. Further, these data suggest that proliferative breast lesions are heterogeneous and may represent non-obligate precursors of invasive carcinoma.

KW - atypical ductal hyperplasia

KW - breast carcinoma

KW - columnar cell change

KW - PIK3CA

KW - usual ductal hyperplasia

UR - http://www.scopus.com/inward/record.url?scp=84899904108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899904108&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2013.197

DO - 10.1038/modpathol.2013.197

M3 - Article

C2 - 24186142

AN - SCOPUS:84899904108

VL - 27

SP - 740

EP - 750

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 5

ER -